Tcr2 Therapeutics Accounts Payable

Tcr2 Therapeutics (TCRR) currently reports a accounts payable of $6.3M as of March 2023. That compares with $4.5M in the prior-year period — up 41.0% year over year. Use the charts on this page to explore Tcr2 Therapeutics's accounts payable history and peer comparisons.

Tcr2 Therapeutics's accounts payable increased from $4.5M to $6.3M — a 41.0% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tcr2 Therapeutics reported $6.3M in accounts payable as of March 2023. That compares with $4.5M in the prior-year period — up 41.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $6.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tcr2 Therapeutics, and consider following TCRR for alerts when major investors trade the stock.

Tcr2 Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $6.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRR with unrelated industries.